Research progress on the kynurenine pathway in the prevention and treatment of Parkinson’s disease

References

• Carrarini C, Russo M, Dono F, Di Pietro M, Rispoli MG, Di Stefano V, Ferri L, Barbone F, Vitale M, Thomas A, et al. A stage-based approach to therapy in Parkinson’s Disease. Biomolecules. 2019;9(8):388.
   PubMed Web of Science ®Google Scholar
• Azeggagh S, Berwick DC. The development of inhibitors of leucine-rich repeat kinase 2 (LRRK2) as a therapeutic strategy for Parkinson’s disease: the current state of play. Br J Pharmacol. 2022;179(8):1478–1495.
   PubMed Web of Science ®Google Scholar
• Li G, Ma J, Cui S, He Y, Xiao Q, Liu J, Chen S. Parkinson’s disease in China: a forty-year growing track of bedside work. Transl Neurodegener. 2019;8:22.
   PubMed Web of Science ®Google Scholar
• Tansey MG, Wallings RL, Houser MC, Herrick MK, Keating CE, Joers V. Inflammation and immune dys function in Parkinson disease. Nat Rev Immunol. 2022;22(11):657–673.
   PubMed Web of Science ®Google Scholar
• Chen Z, Zhang Z-Y, Zhang W, Xie T, Li Y, Xu X-H, Yao H. Direct and indirect pathway neurons in ventrolateral striatum differentially regulate licking movement and nigral responses. Cell Rep. 2021;37(3):109847.
   PubMed Web of Science ®Google Scholar
• Feng Y-S, Yang S-D, Tan Z-X, Wang M-M, Xing Y, Dong F, Zhang F. The benefits and mechanisms of exercise training for Parkinson’s disease. Life Sci. 2020;245:117345.
   PubMed Web of Science ®Google Scholar
• Knott C, Stern G, Wilkin GP. Inflammatory regulators in parkinsons disease: iNOS, Iipocortin-1, and cyclooxygenases-1 and 2. Mol Cell Neurosci. 2000;16(6):724–739.
   PubMed Web of Science ®Google Scholar
• Koprich JB, Reske-Nielsen C, Mithal P, Isacson O. Neuroinflammation mediated by IL-1β increases susceptibility of dopamine neurons to degeneratiion in an animal model of parkinsons disease. J Neuroinflammation. 2008;5:8.
   PubMed Web of Science ®Google Scholar
• Tan E-K, Chao Y-X, West A, Chan L-L, Poewe W, Jankovic J. Parkinson disease and the immune system - associations, mechanisms and therapeutics. Nat Rev Neurol. 2020;16(6):303–318.
   PubMed Web of Science ®Google Scholar
• Mikita T, Campbell D, Wu P, Williamson K, Schindler U. Requirements for interleukin- 4 induced gene expression and function characterizaton of stat6. Mol Cell Biol. 1996;16(10):5811–5820.
   PubMed Web of Science ®Google Scholar
• Fathi M, Vakili K, Yaghoobpoor S, Tavasol A, Jazi K, Hajibeygi R, Shool S, Sodeifian F, Klegeris A, McElhinney A, et al. Dynamic changes in metabolites of the kynurenine pathway in Alzheimer’s disease, Parkinson’s disease, and Huntington’s disease: a systematic review and meta-analysis. Front Immunol. 2022;13:997240.
   PubMed Web of Science ®Google Scholar
• Mor A, Tankiewicz-Kwedlo A, Krupa A, Pawlak D. Role of kynurenine pathway in oxidative stress during neurodegenerative disorders. Cells. 2021;10(7):1603.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Zhang S, Fu P, Zhang Z, Lin K, Ko JK-S, Yung KK-L. Roles of glutamate receptors in Parkinson’s disease. IJMS. 2019;20(18):4391.
   Google Scholar
• Venkatesan D, Iyer M, Narayanasamy A, Siva K, Vellingiri B. Kynurenine pathway in Parkinson’s disease-An update. NeurologicalSci. 2020;21:100270.
   PubMedGoogle Scholar
• Behl T, Kaur I, Sehgal A, Singh S, Bhatia S, Al-Harrasi A, Zengin G, Bumbu AG, Andronie-Cioara FL, Nechifor AC, et al. The footprint of kynurenine pathway in neurodegeneration: janus-faced role in Parkinson’s disorder and therapeutic implications. IJMS. 2021;22(13):6737.
   Google Scholar
• Zhang S, Collier MEW, Heyes DJ, Giorgini F, Scrutton NS. Advantages of brain penetrating inhibitors of kynurenine-3-monooxygenase for treatment of neurodegenerative diseases. Arch Biochem Biophys. 2021;697:108702.
   PubMed Web of Science ®Google Scholar
• Lim CK, Fernández-Gomez FJ, Braidy N, Estrada C, Costa C, Costa S, Bessede A, Fernandez-Villalba E, Zinger A, Herrero MT, et al. Involvement of the kynurenine pathway in the pathogenesis of Parkinson’s disease. Prog Neurobiol. 2017;155:76–95.
   PubMed Web of Science ®Google Scholar
• Zádor F, Joca S, Nagy-Grócz G, Dvorácskó S, Szűcs E, Tömböly C, Benyhe S, Vécsei L. Pro-inflammatory cytokines: potential links between the endocannabinoid system and the kynurenine pathway in depression. IJMS. 2021;22(11):5903.
   Google Scholar
• Brown SJ, Huang XF, Newell KA. The kynurenine pathway in major depression: what we know and where to next. Neurosci Biobehav Rev. 2021;127:917–927.
   PubMed Web of Science ®Google Scholar
• Qin W, Shi Y, Chen W, Jia X, Asakawa T. Can kynurenine pathway be considered as a next-generation therapeutic target for Parkinson’s disease? An update information. Biosci Trends. 2022;16(4):249–256.
   PubMed Web of Science ®Google Scholar
• Morales-Puerto N, Giménez-Gómez P, Pérez-Hernández M, Abuin-Martínez C, Gil de Biedma-Elduayen L, Vidal R, Gutiérrez-López MD, O'Shea E, Colado MI. Addiction and the kynurenine pathway: a new dancing couple? Pharmacol Ther. 2021;223:107807.
   PubMed Web of Science ®Google Scholar
• Ball HJ, Jusof FF, Bakmiwewa SM, Hunt NH, Yuasa HJ. Tryptophan-catabolizing enzymes - party of three. Front Immunol. 2014;5:485.
   PubMed Web of Science ®Google Scholar
• O'Connor JC, André C, Wang Y, Lawson MA, Szegedi SS, Lestage J, Castanon N, Kelley KW, Dantzer R. Interferon-gamma and tumor necrosis factor-alpha mediate the upregulation of indoleamine 2, 3-dioxygenase and the induction of depressive-like behavior in mice in response to bacillus Calmette- Guerin. J Neurosci. 2009;29(13):4200–4209.
   PubMed Web of Science ®Google Scholar
• Huang Y-S, Ogbechi J, Clanchy FI, Williams RO, Stone TW. IDO and kynurenine metabolites in peripheral and CNS disorders. Front Immunol. 2020;11:388.
   PubMed Web of Science ®Google Scholar
• Savitz J. The kynurenine pathway: a finger in every pie. Mol Psychiatry. 2020;25(1):131–147.
   PubMed Web of Science ®Google Scholar
• Ciapała K, Mika J, Rojewska E. The kynurenine pathway as a potential target for neuropathic pain therapy design: from basic research to clinical perspectives. IJMS. 2021;22(20):11055.
   Google Scholar
• Castellano-Gonzalez G, Jacobs KR, Don E, Cole NJ, Adams S, Lim CK, Lovejoy DB, Guillemin GJ. Kynurenine 3-Monooxygenase Activity in Human Primary Neurons and Effect on Cellular Bioenergetics Identifies New Neurotoxic Mechanisms. Neurotox Res. 2019;35(3):530–541.
   PubMed Web of Science ®Google Scholar
• Bai MY, Lovejoy DB, Guillemin GJ, Kozak R, Stone TW, Koola MM. Galantamine-memantine combination and kynurenine pathway enzyme inhibitors in the treatment of neuropsychiatric disorders. Complex Psychiatry. 2021;7(1-2):19–33.
   PubMedGoogle Scholar
• Modoux M, Rolhion N, Mani S, Sokol H. Tryptophan Metabolism as a Pharmacological Target. Trends Pharmacol Sci. 2021;42(1):60–73.
   PubMed Web of Science ®Google Scholar
• Platten M, Nollen EAA, Röhrig UF, Fallarino F, Opitz CA. Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond. Nat Rev Drug Discov. 2019;18(5):379–401.
   PubMed Web of Science ®Google Scholar
• Lovelace MD, Varney B, Sundaram G, Franco NF, Ng ML, Pai S, Lim CK, Guillemin GJ, Brew BJ. Current Evidence for a Role of the Kynurenine Pathway of Tryptophan Metabolism in Multiple Sclerosis. Front Immunol. 2016;7:246.
   PubMed Web of Science ®Google Scholar
• Gorecki AM, Anyaegbu CC, Anderton RS. TLR2 and TLR4 in Parkinson’s disease pathogenesis: the environment takes a toll on the gut. Transl Neurodegener. 2021;10(1):47.
   PubMed Web of Science ®Google Scholar
• Iovino L, Tremblay ME, Civiero L. Glutamate-induced excitotoxicity in Parkinson’s disease: the role of glial cells. J Pharmacol Sci. 2020;144(3):151–164.
   PubMed Web of Science ®Google Scholar
• Latif S, Jahangeer M, Maknoon Razia D, Ashiq M, Ghaffar A, Akram M, El Allam A, Bouyahya A, Garipova L, Ali Shariati M, et al. Dopamine in Parkinson’s disease. Clin Chim Acta. 2021;522:114–126.
   PubMed Web of Science ®Google Scholar
• Joisten N, Ruas JL, Braidy N, Guillemin GJ, Zimmer P. The kynurenine pathway in chronic diseases: a compensatory mechanism or a driving force?. Trends Mol Med. 2021;27(10):946–954.
   PubMed Web of Science ®Google Scholar
• Ogawa T, Matson WR, Beal MF, Myers RH, Bird ED, Milbury P, Saso S. Kynurenine pathway abnormalities in Parkinson’s disease. Neurology. 1992;42(9):1702–1706.
   PubMed Web of Science ®Google Scholar
• Beal MF, Matson WR, Storey E, Milbury P, Ryan EA, Ogawa T, Bird ED. Kynurenic acid concentrations are reduced in Huntington’s disease cerebral cortex. J Neurol Sci. 1992;108(1):80–87.
   PubMed Web of Science ®Google Scholar
• Widner B, Leblhuber F, Fuchs D. Increased neopterin production and tryptophan degradation in advanced Parkinson’s disease. J Neural Transm (Vienna)). 2002;109(2):181–189.
   PubMed Web of Science ®Google Scholar
• Knyihár-Csillik E, Csillik B, Pákáski M, Krisztin-Péva B, Dobó E, Okuno E, Vécsei L. Decreased expression of kynurenine aminotransferase-I (KAT-I) in the substantia nigra of mice after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treatment. Neuroscience. 2004;126(4):899–914.
   PubMed Web of Science ®Google Scholar
• Hartai Z, Klivenyi P, Janaky T, Penke B, Dux L, Vecsei L. Kynurenine metabolism in plasma and in red blood cells in Parkinson’s disease. J Neurol Sci. 2005;239(1):31–35.
   PubMed Web of Science ®Google Scholar
• Heilman PL, Wang EW, Lewis MM, Krzyzanowski S, Capan CD, Burmeister AR, Du G, Escobar Galvis ML, Brundin P, Huang X, et al. Tryptophan metabolites are associated with symptoms and nigral pathology in Parkinson’s disease. Mov Disord. 2020;35(11):2028–2037.
   PubMed Web of Science ®Google Scholar
• Heyes MP, Saito K, Crowley JS, Davis LE, Demitrack MA, DER M, Dilling LA, Elia J, Kruesi MJP, Lackner A, et al. Quinolinic acid and kynurenine pathway metabolism in inflflammatory and noninflammatory neurological disease. Brain. 1992;115(5):1249–1273.
   PubMedGoogle Scholar
• Chang K-H, Cheng M-L, Tang H-Y, Huang C-Y, Wu Y-R, Chen C-M. Alternations of metabolic profifile and kynurenine metabolism in the plasma of Parkinson’s disease. Mol Neurobiol. 2018;55(8):6319–6328.
   PubMed Web of Science ®Google Scholar
• Sorgdrager FJH, Vermeiren Y, Van Faassen M, van der Ley C, Nollen EAA, Kema IP, De Deyn PP. Age- and disease-specific changes of the kynurenine pathway in Parkinson’s and Alzheimer’s disease. J Neurochem. 2019;151(5):656–668.
   PubMed Web of Science ®Google Scholar
• Bai JH, Zheng YL, Yu YP. Urinary kynurenine as a biomarker for Parkinson’s disease. Neurol Sci. 2021;42(2):697–703.
   PubMed Web of Science ®Google Scholar
• Miranda AF, Boegman RJ, Beninger RJ, Jhamandas K. Protection against quinolinic acid-mediated excitotoxicity in nigrostriatal dopaminergic neurons by endogenous kynurenic acid. Neuroscience. 1997;78(4):967–975.
   PubMed Web of Science ®Google Scholar
• Silva-Adaya D, Pérez-De La Cruz V, Villeda-Hernández J, Carrillo-Mora P, González-Herrera IG, García E, Colín-Barenque L, Pedraza-Chaverrí J, Santamaría A. Protective effect of L-kynurenine and probenecid on 6-hydroxydopamine-induced striatal toxicity in rats: implications of modulating kynurenate as a protective strategy. Neurotoxicol Teratol. 2011;33(2):303–312.
   PubMed Web of Science ®Google Scholar
• Fukuyama K, Tanahashi S, Hoshikawa M, Shinagawa R, Okada M. Zonisamide regulates basal ganglia transmission via astroglial kynurenine pathway. Neuropharmacology. 2014;76:137–145.
   PubMed Web of Science ®Google Scholar
• Kubicova L, Chobot V. Potential of kynurenine metabolites in drug development against neurodegenerative diseases. Neural Regen Res. 2021;16(2):308–309.
   PubMed Web of Science ®Google Scholar
• Chen P, Li X. Study on effect of striatal mglur2/3 in alleviating motor dysfun -ction in rat pd model treated by exercise therapy. Front Aging Neurosci. 2019;11:255.
   PubMed Web of Science ®Google Scholar
• Phillips RS, Iradukunda EC, Hughes T, Bowen JP. Modulation of enzyme activity in the kynurenine pathway by kynurenine monooxygenase inhibition. Front Mol Biosci. 2019;6:3.
   PubMed Web of Science ®Google Scholar
• Beaumont V, Mrzljak L, Dijkman U, Freije R, Heins M, Rassoulpour A, Tombaugh G, Gelman S, Bradaia A, Steidl E, et al. The novel KMO inhibitor CHDI-340246 leads to a restoration of electrophysiological alterations in mouse models of Huntington’s disease. Exp Neurol. 2016;282:99–118.
   PubMed Web of Science ®Google Scholar
• Abdel-Magid AF. Kynurenine Monooxygenase (KMO) Inhibitors for the Treatment of Acute Pancreatitis and Neurodegenerative Disorders. ACS Med Chem Lett. 2015;6(9):954–955.
   PubMed Web of Science ®Google Scholar
• Lu Y, Shao M, Wu T. Kynurenine-3-monooxygenase: a new direction for the treatment in different diseases. Food Sci Nutr. 2020;8(2):711–719.
   PubMed Web of Science ®Google Scholar
• Fukushima T, Umino M, Sakamoto T, et al. A review of chromatographic methods for bioactive tryptophan metabolites, kynurenine, kynurenic acid, quinolinic acid, and others, in biological fluids. Biomed Chromatogr. 2022;36:e5308.
   PubMed Web of Science ®Google Scholar
• Harris CA, Miranda AF, Tanguay JJ, Boegman RJ, Beninger RJ, Jhamandas K. Modulation of striatal quinolinate neurotoxicity by elevation of endogenous brain kynurenic acid. Br J Pharmacol. 1998;124(2):391–399.
   PubMed Web of Science ®Google Scholar
• Sodhi RK, Bansal Y, Singh R, Saroj P, Bhandari R, Kumar B, Kuhad A. IDO-1 inhibition protects against neuroinflammation, oxidative stress and mitochondrial dysfunction in 6-OHDA induced murine model of Parkinson’s disease. Neurotoxicology. 2021;84:184–197.
   PubMed Web of Science ®Google Scholar
• van der Goot AT, Zhu W, Vázquez-Manrique RP, Seinstra RI, Dettmer K, Michels H, Farina F, Krijnen J, Melki R, Buijsman RC, et al. Delaying aging and the aging-associated decline in protein homeostasis by inhibition of tryptophan degradation. Proc Natl Acad Sci U S A. 2012;109(37):14912–14917.
   PubMed Web of Science ®Google Scholar
• Perez-Pardo P, Grobben Y, Willemsen-Seegers N, Hartog M, Tutone M, Muller M, Adolfs Y, Pasterkamp RJ, Vu-Pham D, van Doornmalen AM, et al. Pharmacological validation of TDO as a target for Parkinson’s disease. Febs J. 2021;288(14):4311–4331.
   PubMed Web of Science ®Google Scholar
• Nagy K, Plangár I, Tuka B, Gellért L, Varga D, Demeter I, Farkas T, Kis Z, Marosi M, Zádori D, et al. Synthesis and biological effects of some kynurenic acid analogs. Bioorg Med Chem. 2011;19(24):7590–7596.
   PubMed Web of Science ®Google Scholar
• Wu HQ, Lee SC, Schwarcz R. Systemic administration of 4-chlorokynurenine prevents quinolinate neurotoxicity in the rat hippocampus. Eur J Pharmacol. 2000;390(3):267–274.
   PubMed Web of Science ®Google Scholar
• Battaglia G, La Russa M, Bruno V, Arenare L, Ippolito R, Copani A, Bonina F, Nicoletti F. Systemically administered D-glucose conjugates of 7-chlorokynurenic acid are centrally available and exert anticonvulsant activity in rodents. Brain Res. 2000;860(1-2):149–156.
   PubMed Web of Science ®Google Scholar
• Füvesi J, Somlai C, Németh H, Varga H, Kis Z, Farkas T, Károly N, Dobszay M, Penke Z, Penke B, et al. Comparative study on the effects of kynurenic acid and glucosamine-kynurenic acid. Pharmacol Biochem Behav. 2004;77(1):95–102.
   PubMed Web of Science ®Google Scholar
• Luchowska E, Luchowski P, Wielosz M, et al. FK506 attenuates 1 - methy l - 4 - phenylpyridinium - and 3 - nitropropionic acid-evoked inhibition of kynurenic acid synthesis in rat cortical slices. Acta Neurobiol Exp (Wars). 2003;63(2):101–108.
   PubMed Web of Science ®Google Scholar